bioAffinity Technologies (BIAF) Operating Expenses (2021 - 2026)

bioAffinity Technologies (BIAF) has 6 years of Operating Expenses data on file, last reported at $928636.0 in Q1 2026.

• Operating Expenses for Q1 2026 came in at $928636.0, down 32.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.2 million (down 14.02% YoY), and the FY2025 annual result was $16.7 million, down 8.63% from the prior year.
• Operating Expenses eased to $928636.0 in Q1 2026 per BIAF's latest filing, from $4.7 million in the prior quarter.
• Over five years, Operating Expenses peaked at $5.2 million in Q4 2024 and troughed at $685279.0 in Q2 2022.
• A 5-year average of $2.8 million and a median of $2.6 million in 2023 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2023 and 2025: Operating Expenses jumped 180.12% in 2023, then sank 68.57% in 2025.
• A 5-year view of Operating Expenses shows it stood at $1.6 million in 2022, then jumped by 180.12% to $4.6 million in 2023, then rose by 13.13% to $5.2 million in 2024, then decreased by 8.23% to $4.7 million in 2025, then tumbled by 80.37% to $928636.0 in 2026.
• Business Quant data shows BIAF's Operating Expenses at $928636.0 in Q1 2026, $4.7 million in Q4 2025, and $3.7 million in Q3 2025.